Fabrication of microfluidic devices for artificial respiration by Park, Hyesung, Ph. D. Massachusetts Institute of Technology
Fabrication of Microfluidic Devices for Artificial 
Respiration 
by 
Hyesung Park 
B.S. Physics 
Illinois State University, 2004 
SUBMITTED TO THE DEPARTMENT OF MECHANICAL ENGINEERING IN PARTIAL 
FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF 
MASTER OF SCIENCE IN MECHANICAL ENGINEERING 
AT THE 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY 
JUNE 2007 
© 2007 Massachusetts Institute of Technology 
All rights reserved 
Signature of Author: 
Certified by: 
Signature redacted 
Dep~rt){}ent of~~chadical Engineering 
May 21, 2007 
Signature redacted 
Todd Thorsen 
Assistant Profe~sor 1f Mechanical. Engine.~~ing 
Signature redacted ~rvlsor 
Certified by: ________________________ ~~~~--------------\::!~;' ~~_ Richard Gilbert 
Visiting Scientist, Department qJ:"Mechanical Engineering 
..A Thesis Supervisor 
Signature redacted 
Accepted by: ___________ _, __ _ 
, . " Lallit Anand 
MASSACHUSETTS INS E 
OF TECl-iNOLOGY 
Graduate Officer, Department of Mechanical Engineering 
[lli~; i 2007 I 
LIBRARIES 
ARCHIVES 
(This page intentionally left blank)
Fabrication of Microfluidic Devices for Artificial
Respiration
by
Hyesung Park
Submitted to the Department of Mechanical Engineering on May 21,
2007 in Partial Fulfillment of the Requirements for the Degree of Master
of Science in Mechanical Engineering
Abstract
We are developing elastomeric polydimethylsiloxane (PDMS) microfluidic devices incorporated
with photoactive thin films to create an implantable artificial respiration platform. Whereas state-
of-the-art respiration support machines deliver oxygen gas directly to the blood via external
macroscale devices, our technique utilizes a biomimetic photocatalytic process to generate energy
from light and thus produce dissolved oxygen from water which is already present in the blood.
Blood oxygenation will be achieved by the interaction between the photoactivated metal oxide
film and blood in the setting of a molded microfluidic conduit, providing a stable and implantable
oxygenation platform. As a basic, scalable building block, we developed a noble "network"
design which was structurally similar to the native pulmonary capillary network. The
interconnected channel geometry was designed in such a way to minimize shear stress and reduce
hemolysis and thrombosis inside the microchannel. It allowed alternative flow pathways in the
event of single channel occlusion while minimizing the establishment of detrimental pressure
gradients. The hemocompatibility analysis demonstrated that the network construct showed
acceptable levels of hemolysis rate (< 8%) and thrombus formation. Critical to the success of this
project is the understanding of the manufacture parameters for microfluidic devices molded from
elastomeric materials like PDMS. In the initial development of our work, we performed the
following three tasks to generate manufacture protocols for elastomeric microfluidic devices that
will be ultimately used for biological applications: 1) Curing schedules of the heat-cure PDMS
elastomers under various fabrication parameters were characterized. 2) The interlayer bonding
chemistry of the double layer PDMS device was analyzed followed by subsequent mechanical
analysis. 3) The efficacy of various surface treatment techniques on hydrophobic PDMS surfaces
was investigated using fluorescently tagged bacteria (E. Coli) flowed through microchannels as
reporter particles to measure non-specific adhesion, which will provide useful information in
minimizing channel fouling for biological applications.
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Title: Assistant Professor of Mechanical Engineering
Richard Gilbert
Title: Visiting Scientist, Department of Mechanical Engineering
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Chapter 1
Introduction
Major advances in health care over the past several decades have resulted in the reduction
of mortality for most major diseases, such as cancer and cardiovascular disease.
However, few major advances in patients with end-stage lung diseases were achieved
during the same time period. In fact, the death rate of the chronic lung disease has
continued to increase and this is largely due to inadequate means for providing
intermediate and long-term respiratory support. While numerous technical solutions have
been proposed and implemented over the past decades, the availabilty of a platform that
provides a safe, reliable method of blood oxygenation remains elusive. The most
common means for improving gas exchange in patients with acute respiratory failure has
relied on closed, positive-pressure mechanical ventilation system. However, adverse
effects such as oxygen toxicity, altered metabolism, and barotraumas are common, and
these effects may in turn result in further injury to the already failing lungs and add
significantly to morbidity and mortality.
Mechanical ventilation supports have been made possible by extracorporeal
membrane oxygenation (ECMO) and intravenous membrane oxygenation (IVOX)
techniques. Both of these approaches, however, have critical drawbacks which make
them less appropriate for practical application.
ECMO augments oxygenation by promoting gas diffusion across a microporous
membrane and gained a great attention as a mean to restore normal gas exchange.'
Furthermore, technical improvements made this technology possible to be employed
during cardiac bypass.2 - Nonetheless, ECMO suffered from several limitations. This
technology requires a large and complex blood pumping and oxygenator system, and
surgical cannulation. In addition, such membranes exibit frequent protein adsorption and
platelet adhesion, and are associated with bleeding and infection. The natural extension
13
of ECMO was intravenous membrane oxygenation which was based on the ability of
hollow fiber membranes to diffuse oxygen and carbon dioxide. While the IVOX
technology improved oxygenation and hemodynamics, it was still limited by a low level
of gas exchange, high number of adverse events, and device malfunctions.5
One of the most important recent advances in lung therapy has been the
improvement in techniques for performing lung transplantation.6 7 However, this
approach, for several reasons, does not give a desirable solution to patients with chronic
lung diseases either. First, the number of viable donors by far falls short of than the
demand; even if there are enough supplies, temporizing during pre-transplantation is still
very challenging. Also, the highly complex and strict matching process of donor lungs
between the donors and recipients renders the lung transplantation extremely difficult.8-9
Therefore, despite improvement in surgical techniques, methods for obtaining and
preserving donor lungs will be not easily solved in the near future.
While prior ECMO-based efforts have sought to achieve intravascular respiration
by diffusing gases across permeable, thin-walled, hollow fibers, we propose a
fundamentally different approach. Rather than to deliver oxygen gas directly into the
blood, our technology employs photocatalytic energy to generate oxygen from the water
already present in the blood, thereby eliminating the need for exogenous gas delivery.
Photocatalytic processes are routinely used in nature to harness energy from light
in order to drive chemical reactions. For example, photosynthesis utilizes energy derived
from sunlight to drive key metabolic processes in green plants; it is based on the ability of
a metal complex chromophore of magnesium and a transition metal oxide cluster of
manganese to use light energy to produce charge separation, which then results in the
generation of dissolved oxygen. When applied to blood in the manner proposed, DO
binds rapidly to hemoglobin without the conversion to a gas phase. This approach avoids
membrane diffusion barriers associated with hollow fiber technologies and further
eliminates the exposure of tissue and blood to the mechanically disruptive effects of gas
sparging. Therefore, the proposed artificial lung technology will apply these physical
principals to create an artificial system, composed of durable biomimetic materials,
designed to replicate normal respiratory function. The core technology utilizes a robust
semi-conducting metal oxide photolytic thin film, TiO 2 in anatase form, as both the
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photo-absorption element (on the light illumination side) and a DO generating porous
film (on blood contact side). The pores in the TiO2 thin film are nano-scale, which
provides high reaction surface area while preventing blood cells and proteins from direct
contact. TiO2 semi-conductor material is selectively excited by a narrow bandwidth UV
light and thus avoids wasted radiation by transmission. This technology avoids the need
for gas-to-liquid diffusion membranes, pressurized gas, and gas cylinders. By generating
oxygen directly from the water content of whole blood, we eliminate the need for gas
delivery while retaining the full benefit of the red blood cell's ability to rapidly capture
and transport dissolved oxygen.
The overall goal of this research is to develop a high quantum yield photo-
transducing surface, which can be linked to flowing blood at the microfluidic scale in
order to replicate pulmonary capillary respiration.
1.1 Development of Photocatalytic Respiration System
For the past decades, the most common techniques for improving gas exchange in
patients with respiratory failure relied mostly on closed, mechanical ventilation system,
which is based on the delivery of oxygen gas into the bloodstream via gas permeable
hollow fibers.10 -12 The principal weakness of this system is that it requires major
diffusion boundary layers, which results in slowed mass transport since the technology
depends heavily on the membrane diffusivity and differential gas pressure in order to
acheive 0 2/CO 2 exchange, thus in need of a large surface area to achieve sufficient flux
of gases. Furthermore, this system requires a continuous source of exogenous
pressurized oxygen gas as well.
Here, we present an alternative approach for regulating intravascular respiration
in which dissolved oxygen (DO) and oxyhemoglobin are generated from the water
content of whole blood based on the interaction of UV light with a semi-conducting
nanocrystalline titanium dioxide thin film. This idea has already been validated by
showing the possibility of generating dissolved oxygen from the water content of
synthetic serum, based on the interaction of UV light with a semi-conducting titanium
dioxide thin film.' 3 The driving force for this reaction is the displacement of electrons at
CHAPTER 1: INTRODUCTION is
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the photoactive surface following photon absorption. The photo-electronic interaction of
metal chelate chromophores with transition metal oxides forms the basis for light-
dependent oxygen gas generation in photosynthetic (PS) organisms; cyanobacteria, green
algae, phycobilisomes (cyanobacteria and red algae), and higher plants.14 17 The
technology proposed herein builds upon the ability of the semiconducting anatase form of
titanium dioxide, TiO2, to serve both as the chromophore and the charge separation
center 18-21 for such reactions. These results have allowed us to propose a model of
artificial intravascular respiration, based on the ability of transition metal oxides to carry
out optoelectronic conversion, and then to use the resulting charge separation to generate
oxygen from the water content present in whole blood (Figure 1.1). The feasibility of
this photolytic generation of dissolved oxygen and oxyhemoglobin formation in whole
blood has already been demonstrated, a pivotal step in the development of an artificial
technology for autonomous intravascular gas exchange. 13
Water um) RedBlood Serum) Blood Oxygenated
Cell Blood ReturnedDO Out Cl To Patient
Bicarbonate InLight (Blood Serum)
Venous
C02 Out Blood Cell
Whole
C0 2 Exhausted or Blood FromPhoto-Chemically Fixed Patient
Light Source Porous Micro-Fabricated Blood Compartment
Film
Figure 1. 1 Diagram showing the fundamental mechanism of a photolytic DO generation and
oxyhemoglobin formation. The photolytic technology is based on the ability of transition metal
oxides to convert light energy to electric current; the resulting charge separation is used to
generate oxygen from adjacent (non diffusion) water molecules suppliedfrom serum. The
photochemical materials are designed to produce DO directly in an aqueous fluid (blood),
without involving the gaseous phase, which is freely available for binding with hemoglobin. The
photolytic artificial lung technology utilizes a semi-conducting metal oxide material, TiO2, as
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both the photo-absorption element and photochemically driven chemical conversion center. The
light energy produces charge separation (electron-hole pairs) in the semi-conductor, which
results in the production of active oxygen, hydrogen ions andfree electrons.
1.2 Related works and goals
While the ultimate goal of the project is to create an elastomer-based (PDMS) artificial
respiratory platform capable of partially assisting or replacing the human lung, this
platform provided a model system to develop robust manufacture protocols for molded
PDMS microfluidic devices since critical to the success of this project also lies in better
understanding of the manufacture parameters for microfluidic devices molded from
elastomeric materials like PDMS. In the initial development of our work, we
characterized the curing schedules for the heat-cure PDMS elastomers by studying
different monomer/catalyst ratio, curing time, and aspect ratio, which are described in
detail in chapter 2. Once the curing parameters for individual and double-layer PDMS
devices have been established, the interlayer bonding properties of multi-layer devices
were investigated by analyzing the mechanical strength of the device; chapter 3 describes
this in detail. Based on the manufacture protocols developed from chapters 2 and 3,
surface modification protocols for PDMS polymers were investigated in chapter 4.
Several methods, such as polymer coating or grafting, oxygen plasma treatment, and
chemical treatment with strong acid, were discussed and the efficacy of each method was
compared. With the essential fabrication techniques being developed, chapter 5 focuses
on the fundamental technology that lies in the development of artificial respiration device
emphasizing biocompatibility and oxygenation of the prototype device.
CHAPTER 1: INTRODUCTION 17
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Chapter 2
Curing Schedules for PDMS
Elastomers
2.1 Material selection
In order to manufacture such microfluidic devices introduced earlier, we used
polydimethylsiloxane (PDMS), a two-part (monomer/catalyst) elastomeric material
whose ideal mixing ratio is 10:1 parts A:B (Dow Coming Sylgard 184). PDMS is widely
used in the fabrication of microchannel systems for biological applications since features
can be reproduced with high fidelity by replica molding, it is optically transparent
(suitable for detection schemes, e.g., UV absorbance and fluorescence), and it is non-
toxic. Mammalian cells can be cultured directly on PDMS and devices made from it can
be implanted in vivo, and its low curing temperature and ease of fabrication make it ideal
for soft lithography and rapid prototyping.22 Also, PDMS is particularly appropriate for
the oxygenation application due to its high permeability to oxygen gas, whose diffusivity
is approximately 6 x 10-9m 2 s-1.23 Despite the aforementioned benefits of PDMS, its
hydrophobic surface makes it susceptible to non-specific protein adhesion, a particular
concern for microfluidic devices to be used in biological assays. However, both chemical
and physical modifications of the PDMS surface can increase its biocompatibility by
rendering the surface hydrophilic or entropically unfavorable for protein adhesion.
Currently available methods include oxygen plasma treatment, polymer coating or
grafting, and chemical treatment with strong acids.
24
-
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2.2 Fabrication Process
2.2.1 Mold Fabrication
The fundamental technology that is used for the fabrication of the microfluidic device is
based on the soft lithography. Soft lithography is a molding technique using etched or
microfabricated structures created by photolithography as templates to fabricate high-
quality microstructures or nanostructures. Most well known techniques include replica
molding34, microtransfer molding35, microcontact printing36, micromolding in
capillaries37, and solvent-assisted micromolding38 -39 Table 2.1 summarizes the minimum
resolution that can be achieved from each method.
Method Resolution
Replica molding 30 nm
Microtransfer modling 1 Am
Microcontact printing 35 nm
Micromolding in capillaries 1 Rm
Solvent-assisted micromolding 60 nm
Table 2. 1 Various techniques of soft lithography
In soft ligthgraphy, an elastomeric stamp is patterned with relief structures on its
surface. This method makes use of flexible organic materials rather than rigid inorganic
materials which are commonly used in micro-electro-mechanical systems and provides a
simple, low-cost method for micro- and nanostructure fabrication. Figure 2.1 illustrates
general process for soft lithography, the so called rapid prototyping procedure; Once the
design for the desired device is created using computer aided design (CAD) program, the
pattern is transferred to a transparency mask from a high resolution printer (3550 dpi,
Mikacolor, CA). Master for replica molding is prepared from negative (SU-8 50,
Micochem) photoresist on a 3" silicon wafer (Silicon Quest, CA) at Experimental
20
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Materials Laboratory (EML) from MIT following standard photolithography processes: 
negative photoresist was spun coated at 1000 rpm for 45 seconds on a silicon wafer to 
produce 100 f.!m high channels followed by pre-bake, UV exposure, post bake, and 
development. 
Figure 2. 1 Rapid prototyping procedure for soft-lithography.40 The overall procedure from the 
device design to the stamping takes less than 24hours to complete. 
2.2.2 Device Fabrication
Figure 2.2 describes the overall process for both the single and double layer microfluidic
device fabrication. The 2D structure of microfluidic device was fabricated from poly
(dimethylsiloxane) (PDMS) by replica molding from the master that has already been
prepared. 5:1 monomer/catalyst mixture was mixed and degassed and then poured on the
control mold to approximately 5 mm thickness (thick gas layer). This mold was again
degassed under vacuum to remove air bubbles generated while PDMS was poured onto
the mold. At the same time, 20:1 mixture of PDMS was prepared and spin-coated at
1000 rpm for 60 seconds onto the flow mold to 120 gm thickness (thin flow layer)
yielding approximately 20 pm thickness membrane between the control and flow layer.
Both molds were individually baked at 80*C for 11 to 19 minutes. Before coating the
molds with PDMS, they were first treated with silane (high molecular trichloro-
perfluorooctyl silane, Aldrich) for 10 minutes to prevent the adhesion of the PDMS onto
the molds and enable easy mold release of the PDMS structure. After the primary bake,
the partially cured control layer was peeled off from the mold, holes for the inlets and
outlets were punched with a 20G surgical steel Luer Stub (BD), and optically aligned to
the flow layer under a microscope. It is important to note that mask for the control layer
needs to be scaled to 101.7 % in order to account for the shrinkage of the thick layer of
PDMS during curing. This two-layer structure was again baked in an oven for additional
3 hours at 80*C to form a strong covalent bond between the two layers. During this
secondary baking period, the two layers of PDMS, each of which has an excess of
monomer and catalyst, start to cross-link resulting in a monolithic structure.4 ' After the
secondary bake, the final structure was cut and peeled off from the mold and bonded onto
the glass slide via oxygen plasma to seal the flow channel, thus completing the
fabrication process. Oxygen plasma bond provides a strong irreversible bond between
the PDMS structure and the substrate which can withstand pressures up to 30 - 50 psi. 22
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Photoresist spin coated on the silicon wafer
I I 1 I
UV exposure to the photoresist through mask
Develop photoresist
Fabrication of two-layer structure:
Top layer (5:1)
Bottom layer (20:1)Cast PDMS onto the mold
Peel-off PDMS and puch inlets and outlets
photoresist
Silicon wafer
PDMS
UV
mask
Bond to the substrate
Fabrication process of PDMS device: Single Layer glass substrate
Figure 2. 2 Schematic diagram ofthe mold fabrication process: Left column depicts the
fabrication process of a single layer device and the right column describes multi-layer
fabrication process.
20:1
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2.3 Experimental and Results
To establish curing schedules for the heat-cure PDMS elastomers, we developed a PDMS
bonding table for two-layer microfluidic devices whose monomer/catalyst mixing ratios
were 5: 1 and 20:1 respectively. Individual layers of PDMS were cured at 80'C in an
oven and secondary baking time was fixed for 3 hours. Microfludic test devices,
described in Figure 2.3, were fabricated by varying the primary curing time and feature
size (aspect ratio) while keeping the channel height constant at 100 gm: Channel widths
were varied from 1.920 mm (which is somewhat large in terms of microfluidic scale)
down to 0.587 mm. The primary curing time of individual layers was varied from 11 to
19 minutes.
Figure 2. 3 Left: Schematic diagram of mesh type microfludic device. This device mimics the
pulmonary alveolus structure of human lungs. Both top and bottom layers have the same
configuration. The dimensions of each mesh (dark square) and channel (white region) width
have the same length scale. Flow inlet and outlet are punched on the top and bottom circular
channel regions. Each mold for the two layers consists of 100 pm high microchannels
constructed from negative SU-8 photoresist photolithographycally patterned on a silicon wafer.
Right: Diagram of double layer device. White arrow indicates flow channel and red arrow
indicates gas channel.
4
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The effective bonding between the two layers of PDMS was visually confirmed
after the final structure of PDMS devices were peeled off from the mold. Properly
bonded structures completely came off from the mold whereas inefficiently bonded
structures did not entirely come off resulting in tearing the bottom (thin) layer of PDMS.
There were even occasions where the inter-layer bonding was so weak that the top (thick)
layer alone came off from the mold which was still entirely coated with a thin layer of
PDMS.
A primary cure time of 15 minutes was found to be sufficient enough to release
the thick (5:1) PDMS layer from its respective mold, and create a firm PDMS surface on
the spin-coated wafer. Crude layer-layer adhesion tests were carried out after the
secondary baking step, using tweezers to try to mechanically separate the layers
(precision tests done in Chapter 3 using the Zwick/Roell testing machine in the Materials
Laboratory at MIT). Excellent covalent bonding was observed for the narrower channels
(0.59 mm to 0.84 mm) with primary cure times between 15 and 19 minutes. After 19
minutes, the layers were overcured, and frequent layer-layer adhesion failure was
observed. For channels with larger widths (1.20 mm and above), creeping of the
elastomer up and over, and along the edges of microchannels on the spin-coated mold
was observed, which created an uneven surface profile of PDMS that led to inefficient
layer-layer adhesion. This creeping elastomer caused formation of air pockets between
the top and bottom layer when they were brought into contact and lessened the strength
of layer-layer adhesion. Frequent adhesion failure was also observed for thin layer
(bottom layer) microchannels with high aspect ratios (defined as width/height, >10:1).
Even for the devices with well-bonded structures, they sometimes could not be
considered as successful because the thin inter-layer membrane stuck to the top surface of
the thick upper layer (top layer) microchannels thus blockading the channels in the top
layer. Both the successful and unsuccessful bonding of the double layer devices are
illustrated in Figure 2.4.
25
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Figure 2. 4 Cross-sectional view of the two layer microfluidic device. A: Channels in which 
inter layer membrane stuck to the top surface of the gas layer. B: Diagram of successful 
fabrication of two layer device. 
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Creeping of the elastomer around the microchannels can be improved by simply 
increasing the height ofPDMS layers spun coated on the mold by reducing the rpm of 
spin coater. Experiments demonstrated that reducing the rpm from 1000 to 800 greatly 
improved the creeping regions over and around microchannels thereby removing regions 
trapped with air pockets. Letting the spin-coated PDMS mold sit for a while (1-2 hours) 
also helped keeping the elastomer from creeping up and over the microchannels. On the 
other hand, the problem of inter-layer membrane attachment can be simply resolved by 
increasing the channel height of the top layer. 
1.92 mm 1.71 mm 1.20 mm 0.84mm 0.59 mm 
(45mm x45mm) (45mm x45mm) (23mm x35mm) (23mm x23mm) (23mm x23mm) 
11 min Incomplete curing of each layer 
13 min Incomplete curing of each layer 
15 min X X X 0 0 
17 min X X X 0 0 
19 min X X X 0 0 
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Table 2. 2 Double layer of PDMS bonding table established by varying primary curing time and
channel size (aspect ratio). O/X indicates layer-layer bonding success/failure.
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Chapter 3
Interlayer Bonding Chemistry and
Mechanics
In microfluidic structures with multiple layers, it is critical to verify the layer-layer
bonding strength is sufficient to withstand any applied external pressure through the
microchannels in order to prevent any channel leakage activity. Fortunately, the flow
rate implemented in most microfluidic devices is in general quite slow, on the order of
microliters per minute, with corresponding pressures of tens to hundreds of Pascal.
Therefore, for most of the applications, thermal or plasma bonding provides enough
sealing to work with in microfluidics. However, better understanding of the interlayer
bonding chemistry and mechanics would provide useful information not only for the
individual devices to be analyzed in research but in developing appropriate manufacture
protocols in industry as well.
In this chapter, layer-layer adhesion characteristics were investigated for
multilayer molded PDMS-based microfluidic devices. Bonding chemistry was analyzed
as a function of catalyst ratio in individual layers, cure temperature, and interlayer surface
area. Subsequent mechanical analysis of the bonded layers was conducted by measuring
the force (both shear and normal force) required to separate the layers, and optical
analysis of the separated parts was conducted to assess failure mode (simple
delamination, tearing, etc.). Additional mechanical layer-layer adhesion tests were
performed by applying pressure through microchannels whose boundaries are formed by
the layer interface, looking for channel burst activity as a function of applied pressure.
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3.1 Shear Stress
Shear Stress can be easily calculated by the applied force divided by the interlayer
surface area between the top and bottom layers of PDMS.
F
r=- (1)
A
where r is shear stress, F is applied force (shear load), and A is the area of layer
interface (area resisting shear). Strictly speaking, eq. (1) must be interpreted as the
average shear stress. However, since the distribution of direct shear stress is usually
complex and not easily determined, it is common practice to assume that the shear force
F is uniformly distributed over the shear area A.
3.1.1 Device description
In order to determine the test platform for the shear stress test on the multi-layer PDMS
devices, several prototypes were investigated.
30
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Figure 3. 1 Evolution of the test platforms for shear stress
Initially, the two layers of PDMS were thermally bonded, using layers with
different catalyst ratios to form a covalent bond at the interface, with some offset so that
each end of the layers could be placed on the clamp of the Zwick machine. This model
turned out to be extremely inappropriate. PDMS, for being elastomer material, deformed
greatly, especially for the higher ratios of monomer/catalyst layers, while the clamp was
being tightened; this distorted the applied force to the interface between the two layers
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and often times caused splits at the edges of the interlayer surface even before the force is
applied to the test device.
In order to overcome the deformation issue, test samples were attached to glass
slides via oxygen plasma bonding. At the ends of the glass slide, posts were mounted,
which was about the same height as the individual layers of PDMS, so that the external
force could be applied uniaxially. The choice of a fragile material like glass as the
substrate for the test sample over other materials, such as metal or wood, was to minimize
any rotational motion of the sample while the force was applied to the sample. If there
was any significant rotational movement of the sample, which occurred from time to time
during the experiment, the glass slides were broken before the external force had any
noticeable impact on the sample. Furthermore, attaching PDMS to materials like wood
or metal is also challenging; since PDMS is hydrophobic material, conventional glues
would not work on PDMS surface. One trick that can be used, however, is to treat the
surface of PDMS with oxygen plasma since exposing PDMS to plasma oxidation renders
the surface hydrophilic and aqueous solutions can easily wet the oxidized surfaces.
However, the oxidized surface of PDMS is very unstable in air and reverts to being
hydrophobic in less than 30 minutes. Nonetheless, experiments demonstrated that
samples prepared in this way experienced, in most cases, failure of the bonding between
the sample and glass slide while force was applied.
The drawback with the second model was the frequent tearing of PDMS at the
interface where the offset between the two layers began during the application of the
force to the specimen, rendering it hard to observe the desired interlayer failure mode.
When external loads were applied, the downward or upward movement of the edge
around the interlayer surface was pulling the other contacting surface of PDMS layer.
This first caused tearing of surface along the edge, then subsequent tearing of the PDMS
underneath the edge. One might assume that this is the inter-layer failure mode due to
the applied external force and conclude that the specimen could withstand that specific
amount of force to break the interlayer bond. However, the tearing around the edge
would not have happened if both layers of the same dimension were placed precisely on
top of each other, as shown in the 3rd generation schematic, thus resulting in the increase
of threshold of applied external force required to break the layer-layer adhesion.
3
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Therefore, we adopted the 3rd generation model as the test platform for future 
experiments, in which the offset between the two layers of PDMS was removed and top 
and bottom layers of the same dimensions were aligned exactly on top of each other. 
Figure 3.2 illustrates the actual test sample that has been used. 
Figure 3. 2 Description of the shear stress test device. 
3.1.2 Experimental and Results 
In order to analyze the bond strength of the cure bonded double layer PDMS structure by 
measuring the shear force required to break the layer-layer adhesion, test samples were 
prepared by varying three parameters: catalyst/monomer ratio, secondary cure time, and 
interlayer surface area. Four sets of catalyst/monomer ratios for the double layer 
structure were investigated; 1:3/1:30, 1:4/1:25, 1:5/1:20, and 1:611:15. Two sets of 
secondary cure time were tested; 3 hours and 14 hours while primary curing time was 
kept between 16 and 18 minutes for excess catalyst layers and 66 to 98 minutes for 
excess monomer layers. Two sets of sample dimensions were analyzed; 20 mm x 30mm 
and 20mm x 15 mm while the height of both layers were maintained at 4 ,..., 5 mm. These 
test parameters are summarized below. 
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Experimental protocols:
A) Primary Bake Time (at 80'C)
0 1:3 ~ 16 min
1:30 - 80 min + 16 min
0 1:4 ~ 17 min
1:25 - 70 min + 16 min
9 1:5 - 18 min
1:20 -60 min + 18 min
0 1:6 - 18 min
1:15 -50 min + 18 min
B) Secondary Bake Time (at 80*C)
* 3 hours
0 14 hours
C) Interlayer surface dimension
" 20 mm x 15 mm
" 20 mm x 30 mm
Two failure modes on the sample were observed from the applied shear force.
One of them was the interlayer bond break and the other was PDMS layer tearing which
occurred at the weakest point of the bonding, i.e. the interface between the PDMS layer
and glass slide, before the interlayer bond failure.
Experiments demonstrated that, for the fixed secondary curing time and interface
dimensions, the overall bond strength increased from the 1:6/1:15 device to the 1:4/1:25
device. However, it was hard to characterize the bond strength of the 1:3/1:30 samples
since these samples were so rubbery resulting in very frequent PDMS tearing at thel:30
layers before we could observe any adhesion failure. When interface dimensions and
catalyst/monomer ratios were kept constant, the overall bond strength turned out to be
higher for samples with longer secondary baking time. Varying the interlayer surface
area while keeping the polymer mixing ratio and secondary curing time constant yielded
an interesting outcome. For 14 hours secondary baking time, it took more force to
separate samples with larger interlayer surface area. However, the opposite phenomenon
was observed for 3 hours secondary cure time; more force was required to break the
interlayer bonding for samples with smaller interlayer surface area. This phenomenon
3
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might be explained from the fact that 3 hours of secondary curing did not provide
sufficient time for the devices with larger interlayer surface area to have as good of bond
strength as the devices with smaller interlayer surface area. Figure 3.3 illustrates the
distribution of the shear stress for different combination of parameters and table 3.1
shows the maximum values at each of these combinations.
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Mixing Ratio (Catalyst: Monomer) = 1:3 & 1:30
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Mixing Ratio (Catalyst: Monomer)= 1:5 & 1:20
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Figure 3. 3 Distribution of shear stress. Big circular sample points indicate PDMS tearing
failure mode at the weakest point
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Shear stress (kPa /psi) 1:3 / 1:30 1:4 / 1:25 1:5 / 1:20 1:6 / 1:15
20mmxl5mm 116.4/16.9 144.8/21.0 92.9/13.5 83.8/12.2
3hour
20mmx30mm 80.8/ 11.7 93.0/13.5 72.1 / 10.5 64.5 /9.4
20mmxl5mm 138.7 / 20.1 188.4 / 27.3 175.9 / 25.5 125.8 / 18.2
14hour
20mmx30mm 171.7 / 24.9 211.8 / 30.7 200.2 / 29.0 139.8 / 20.3
Table 3. 1 Maximum values of shear stress for each combination ofparameters.
3.2 Normal stress
Normal stress was investigated in a similar manner as the shear stress except now the
applied force was in the direction perpendicular to the interlayer surface.
3.2.1 Device Description
PDMS samples were prepared in the same way as the shear stress test samples. These
two layer devices were treated with oxygen plasma and bonded to the glass slides.
Subsequently, T-shape aluminum pieces were attached to these glass slides completing
the fabrication of the test platform. Figure 3.4 illustrates the schematic and actual test
samples.
8
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Li GlassPDMS-. Aluminum- Clamp
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Figure 3. 4 Left:
the test device
Schematic diagram of the normal stress test platform. Right: Description of
3.2.2 Experimental and Results
Bond strength of the two layer PDMS devices was investigated by measuring the normal
stress required to break the interlayer adhesion. The parameters varied in preparation of
the test samples were the same as the shear stress case.
Similarly to the shear stress test, two failure modes, interlayer bond break and
PDMS tearing at the weakest point, were observed. The observed values of the normal
stress fluctuated a lot more than those from shear stress test. One common trend was the
dominant PDMS failure mode (tearing in weakest spot) observed in 1:3/1:30 devices.
Therefore, one might deduce that this specific mixing ratio would yield the strongest
layer-layer adhesion in the heat cured double layer device. Furthermore, the effect of
interlayer surface area was found to be more significant in the normal stress test: more
force required in breaking the layer-layer adhesion for samples with larger interlayer
39
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surface area. Also, longer secondary baking time produced more robust interlayer
bonding in overall. Figure 3.5 illustrates the distribution of the normal stress for different
combinations of parameters and table 3.2 shows the maximum values at each of these
combinations.
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Mixing Ratio (Catalyst: Monomer)= 1:3 & 1:30
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Mixing Ratio (Catalyst: Monomer) = 1:5 & 1:20
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Mixing Ratio (Catalyst: Monomer) = 1:6 & 1:15
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Figure 3. 5 Distribution of normal stress. Big circular sample points indicate PDMS tearing
failure mode
2 3
- 20by15_14HR: AVG(124.6) / STD(5.9)
20by3Ol4HR: AVG(187.4) / STD(30.8)
-*-20by15_3HR AVG(108.3) / STD(18.6)
-*- 20by30_3HR AVG(135.9) / STD(45.6)
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Normal stress (kPa / psi) 1:3 / 1:30 1:4 / 1:25 1:5 / 1:20 1:6 / 1:15
20mmxl5mm 191.8/27.8 149.4/21.7 131.5 / 19.1 156.0/22.6
3hour
20mmx30mm 249.8 / 36.2 207.2 / 30.1 197.5 / 28.6 172.1 / 25.0
20mmxl5mm 236.4 / 34.3 264.4/38.3 133.5 / 19.4 149.7 /21.7
14hour
20mmx30mm 299.5 / 43.4 379.0 / 55.0 232.9 / 33.8 306.6 / 44.5
Table 3. 2 Maximum values of normal stress for each combination ofparameters.
3.3 Interlayer Burst Analysis
Previous shear and normal tests were conducted with samples in which no microchannels
were patterned by directly applying mechanical forces to the samples. In order to
investigate more realistic situations in microfluidic settings, interlayer burst tests were
performed; Top layers of the PDMS were patterned with microchannels and cure bonded
to another PDMS substrate layers. Nitrogen gas was directly flown inside the
microchannels in order to determine the critical pressure at which interlayer burst occurs.
3.3.1 Device Description
The mold for microchannels was fabricated using standard photolithography. The top
layer was replica molded from this master and then cure bonded to the blank PDMS
substrate layer. Figures 3.6 and 3.7 illustrates the schematic diagrams and actual images
of the test sample.
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Figure 3. 6 Schematic diagram of the burst test device. Left: Top view of the device. Right: 
Three dimensional description of the device with cross-sectional view. 
Figure 3. 7 Description of the burst test device 
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3.3.2 Experimental and Results
Interlayer burst mode was observed by directly blowing nitrogen gas through the
microchannels. The applied pressure was varied from 0 up to approximately 50 psi until
the channel burst activity was observed. Layer-layer adhesion failure was easily
confirmed by the popping sound which occurred when the sealed channels burst.
Interlayer failure was subsequently visually confirmed without any difficulty Test
samples were prepared using the same parameters as shear and normal stress test except
the device dimensions fixed. Apparently, the burst of interlayer bonding occurred around
the microchannels centered in the PDMS device.
This test produced the most reliable results in characterizing the layer-layer
adhesion property. The observed pressure values for samples with distinct sets of
parameters were consistent with one another to a great extent. The bond strength
increased from the 1:6/1:15 device to the 1:3/1:30 device for samples with fixed
secondary curing time. Under the constant catalyst/monomer ratios, the strength of layer-
layer adhesion of samples with 14 hour secondary bake was higher that those of 3 hour
bake.
Additional test with fluid was conducted as well and the result for the burst
pressure was in good agreement with the gas driven burst case. Figure 3.8 illustrates the
distribution of the burst pressure for different combination of parameters and table 3.3
shows the maximum values at each of these combinations.
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Figure 3. 8 Distribution of the applied pressures required to burst the microchannels at the
interface between the top and bottom layer of PDMS.
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Pressure (psi) 1:3 / 1:30 1:4 / 1:25 1:5 / 1:20 1:6 / 1:15
3 hour 42.4 36.4 28.7 23.8
14 hour 50.1 45.0 34.0 27.5
Table 3. 3 Maximum values of the burst pressure for each combination ofparameters.
Pressure (psi) 1:3 / 1:30 1:4 / 1:25 1:5 / 1:20 1:6 / 1:15
3 hour 42.5 36.0 27.0 23.5
14 hour 50.0 45.0 32.0 27.5
Table 3. 4 Burst pressures for liquid.
3.4 Conclusion
Multilayer microfluidic devices that are thermally bonded form a strong covalent bonding
which provides enough sealing upon the exposure of external pressure in most of the
practical application. This chapter investigated the interlayer bonding chemistry and
mechanics of double layer elastomeric PDMS devices by varying several parameters,
such as catalyst/monomer ratios, secondary curing time while fixing the primary curing
time for each of different sets of catalyst/monomer ratio, and interlayer surface area.
Three types of mechanical analysis, shear and normal stress, and interlayer burst activity,
were performed on test devices with different combinations of parameters. All three tests
yielded similar and reproducible results. As the catalyst/monomer ratio increases further
away from the ideal mixing ratio of 1:10, the adhesion strength between the layers
increased accordingly. Furthermore, increasing secondary curing time and the interlayer
surface area seemed to enhance the bonding strength as well although the effect of
47
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interlayer surface area did not seem to be as critical as that of catalyst/monomer ratio and
secondary curing time.
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Chapter 4
Surface Modification of PDMS
Elastomers
While silicone rubber (PDMS) is easy to mold and has superior optical clarity, its
hydrophobic surface makes it susceptible to non-specific protein adhesion and other
hydrophobic species, a particular concern for microfluidic devices to be used in
biological assays. Furthermore, hydrophobic channels are difficult to wet with aqueous
solutions and easily nucleate bubbles inside the channel. Both chemical and physical
modifications of the PDMS surface can increase its biocompatibility, rendering the
surface hydrophilic or entropically unfavorable for protein adhesion. These procedures
include oxygen plasma treatment, polymer coating or grafting, and chemical treatments
with strong acids. In this section, we compared the efficacy of the several surface
treatment methods by using fluorescently tagged bacteria (E. coli) flowed through
microchannels as reporter particles to measure non-specific adhesion.
4.1 Device Description
Microchannels were fabricated from PDMS using soft-lithography and the mold was
prepared from SU8-50 negative photoresist. The channels were 50 gm wide and 40 gm
high. Once the PDMS device has been fabricated, it was thermally bonded to the cover
slip that has been spun coated with PDMS to 20 Rm thickness at 4200 rpm. The cover
slip needed to be coated with PDMS so that all the channel walls were surrounded by
PDMS.
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Figure 4. 1 Diagram of the surface modification test device. Microchannels are 6 mm long, 50 
flm wide, and 40 flm high. 
4.2 E. Coli Preparation 
50 
Medium (ATCC medium: #294 Broth) A mixture of 0.8g of Tryptone (BD 211705), 
0.05g ofNaCI, and 100ml ofDI water was prepared and autoclaved at 121 °C for 30 min. 
E. Coli (Escherichia coli ATCC® 10798 TM) The entire pellet of E. coli was mixed with 6 
ml of the medium and cultured at 37°C for 24 hours at 170 rpm. E. coli solution was then 
stained with the blue fluorescent DAPI nucleic acid stain (excitation / emission maxima: 
358 / 461 nm, Invitrogen) at 1: 1 volumetric ratio in order to observe and count individual 
E. coli particles under the fluorescent microscope. 
4.3 Oxygen Plasma 
PDMS has repeating units of -O-Si(CH3)2-groups and this chemical structure leads to a 
hydrophobic surface. Exposing PDMS surface to air or oxygen plasma introduces silanol 
groups (Si-OH) at the expense of methyl groups (Si-CH3) on the surface and changes the 
surface property from hydrophobic to hydrophilic due to the presence of silanol groups, 
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whereas unmodified PDMS surface is hydrophobic and thus difficult to wet the surface
with aqueous solutions and susceptible to other hydrophobic species.43-45 Channels that
have been treated with plasma can be kept hydrophilic indefinitely by keeping the
surfaces in contact with water or polar organic solvents; otherwise surface
rearrangements may occur over time that bring new hydrophobic groups to the surface to
lower the surface free energy.46
Furthermore, oxidization using plasma produces silanol groups on PDMS and -
OH-containing functional groups on the other materials. These polar groups form
covalent -O-Si-O-bonds with oxidized PDMS when these surfaces are brought into
conformal contact.47 For PDMS and glass, this reaction yields Si-O-Si bonds after loss of
water; These covalent bonds form the basis of a tight, irreversible seal.46' -
4.3.1 Methods
For the plasma experiment, the PDMS device and the substrate were not thermally
bonded. Instead, each part was exposed to the oxygen plasma for 30 seconds at 100 Watt
(SPI Plasma-Prep II) and brought into conformal contact forming an irreversible bonding.
4.4 Ultra-Violet Graft Polymerization
In this section, a one-step procedure to covalently link polymers to the surface of PDMS
microchannels by ultraviolet graft polymerization was utilized. Two materials, acrylic
acid and 2(dimethylamino)ethyl methacrylate (DMAEMA), were used to graft onto
PDMS to yield hydrophilic surfaces. Graft polymerization involves creation of reactive
sites (radicals) on the polymer surface followed by covalent linkage of a preformed
polymer or more commonly a monomer that can then be used as the initiation site for a
polymeric chain. Radicals on a previously inert polymer surface can be created by
various methods such as application of chemical reagents or by exposure to ionizing
radiation or ultraviolet (UV) light. In particular, UV graft polymerization is getting more
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attention over the other methods since it involves fewer steps and possesses low or no
penetration into the bulk polymer.4 ' 47-50
4.4.1 Materials
Acrylic acid (Fluka)
DMAEMA (2(dimethylamino)ethyl methacrylate, Aldrich)
NaIO4 (sodium (meta)periodate, Sigma)
Benzyl Alcohol (Aldrich)
Photoinitiator (Irgacure 500, mixture of benzophenone and 1-Hydroxycyclohexyl phenyl
ketone, Ciba)
4.4.2 Methods
Surface graft polymerization was carried out by the method reported in the using the
protocol of E. Uchida et al.51 First off, an aqueous solution containing NaIO4 (0.5mM),
benzyl alcohol (0.5 wt %) was prepared. Then, each monomer of Acrylic acid (10 wt %)
and DMAEMA (1 wt %) were added to this solution. Each mixture was thoroughly
mixed using magnetic stir bar for two hours. Inclusion of benzyl alcohol in the monomer
solution have been reported to substantially increase the efficiency of surface grafting. 2
53 Microchannels were filled with the final mixtures and exposed to UV (Electrolite,
ELC-500, 9Wx4) for 30 min. After the irradiation, the channels were flushed with
deionized (DI) water via syringe pump at the flow rate of 2 Rl/min for 2hours to remove
residual surface homopolymer. E. coil solution was perfused via syringe pump at the
flow rate of 1 gl/min for 1 and 3 hours after 1 and 48 hours of surface modification.
Then, the channels were flushed with DI water via syringe pump at the flow rate of 5
p1/min for 30 min.
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4.5 Non-UV based Graft Polymerization
Non UV-based polyethylene glycol (PEG) grafts were used to modify the surface of
PDMS using the protocol of S. Hu et al.54 Instead of UV light, PDMS polymerizes as
SiH groups react with vinyl groups in the presence of a Pt catalyst.55
4.5.1 Materials
Pt catalyst (chloroplantinic acid, Aldrich)
DAPEG (diacrylated polyethylene glycol SR610, Sartomer)
4.5.2 Methods
A mixture of DAPEG and Pt catalyst was prepared at the volumetric ration of 200:1. The
mixture was thoroughly mixed using magnetic stir bar for 2 hours. This mixed solution
was then fed into the syringe and the microchannels were completely filled with. Next,
the PDMS device filled with mixture of DAPEG and Pt catalyst was baked in the
conventional oven at 80'C for 30 min. Finally, the DAPEG mixture was flushed out of
the device with DI water via syringe pump (Harvard, MA) at the flow rate of 5 pl/min for
2 hours to completely remove any residual of the mixture. E. coli solution was flowed
through the channels via syringe pump at the flow rate of 1 gl/min for 1 and 3 hours after
1 and 48 hours after the preparation of the test device. After the channels were exposed
to E. coli, they were flushed with DI water via syringe pump at the flow rate of 5 1/min
for 30 min.
4.6 Results
Four different sets of experiment with four different surface modification methods were
investigated; E. coli was continuously flowed for one and three hours after one and forty-
eight hours of surface treatment. After E. coli was perfused inside the channel, photos of
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the microchannels were recorded (XCD-V50, SONY) and additional photos were taken
after E. coli was flushed with DI water (Figures 4.2 and 4.3). Figure 4.2 shows images of
the microchannels after E.coli was flowed at the flow rate of 1 l/min (A-1, B-1, and C-1)
and then flushed with DI water (A-2, B-2, and C-2) at 5 jl/min. Channels A and B are
untreated while channel C has been treated with acrylic acid. E. coli has been stained
(dye) in channels B and C. One of the most well-known defects of PDMS, non-specific
protein adhesion on the surface, is observed in B-2. Although the channels were flushed
with DI water for 30 minutes, most of the E. coli particles were still adherent inside the
channel. However, once the channel was treated with acrylic acid, great improvements
on non-specific adhesion was observed (C-2). The other three methods also improved the
channel fouling to different degrees.
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Figure 4. 2 Photos of channels before and after the channels were flushed with DI water after E. 
coli was flown through the channel. White dots in pictures Band C indicate fluorescently tagged 
E. coli 1: After E. coli flow 2: After flushed with DI water A: Non treated channels without 
fluorescently tagged E. coli B: Non treated channels with fluorescently tagged E. coli C: 
Channels treated with Acrylic acid 
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Figure 4.3 Magnified image ofC-2from Figure 4.2 
To assess treatment efficacv, the number of E. coli particles before and after the 
DI-water-flush were counted in the image captures of the microchannels. The actual 
counts of the E. coli particles from four different surface treatments are summarized in 
Tables 4.1 to 4.5 and visualized with bar graphs in Figures 4.4 to 4.7. The efficacy of 
these four different methods on the degree of E. coli adhesion inside the channel was 
evaluated and compared to the untreated control channels. 
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Control 1 hour run 3 hours run
# of E. Coli Before After Before After
Trial_1 119.0 30.0 120.0 44.0
Trial_2 104.0 38.0 127.0 46.0
Trial_3 108.0 32.0 118.0 45.0
Trial_4 120.0 34.0 124.0 53.0
Trial_5 101.0 36.0 134.0 52.0
Average 110.4 34.0 124.6 48.0
Standard 8.7 3.2 6.3 4.2Deviation
Table 4. 1 Control: Number of E. coli inside the channel before and after channels were flushed
with DI water after E. coli was perfused.
Acrylic Acid 1 hour after 48 hours after
1 hour run 3 hours run 1 hour run 3 hours run
# of E. Coli Before After Before After Before After Before After
Trial_1 98.0 3.0 134.0 5.0 124.0 12.0 116.0 4.0
Trial_2 111.0 4.0 128.0 5.0 128.0 7.0 109.0 5.0
Trial_3 115.0 3.0 117.0 4.0 123.0 5.0 123.0 4.0
Trial_4 131.0 4.0 128.0 4.0 121.0 6.0 111.0 5.0
Trial_5 121.0 6.0 121.0 5.0 122.0 8.0 108.0 5.0
Average 115.2 4 125.6 4.6 123.6 7.6 113.4 4.6
Deviatin 12.21 1.22 6.7 0.6 2.7 2.7 6.2 0.6
Table 4. 2 Acrylic acid: Number of E. coli inside the channel before and after channels were
flushed with DI water after E. coli was perfused.
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xygen Plasma 1 hour after 48 hours after
1 hour run 3 hours run 1 hour run 3 hours run
# of E. Coil Before After Before After Before After Before After
Trial_1 111.0 6.0 108.0 10.0 107.0 4.0 111.0 9.0
Trial_2 126.0 3.0 115.0 10.0 111.0 5.0 100.0 10.0
Trial_3 115.0 5.0 100.0 9.0 95.0 7.0 102.0 7.0
Trial_4 99.0 3.0 94.0 8.0 104.0 6.0 105.0 13.0
Trial_5 110.0 3.0 103.0 7.0 123.0 5.0 112.0 10.0
Average 112.2 4.0 104.0 8.8 108.0 5.0 106.0 9.8
Standard 9.7 1.4 8.0 1.3 10.3 1.1 5.3 2.2Deviation IIII
Table 4. 3 Oxygen Plasma: Number of E. coli inside the channel before and after channels were
flushed with DI water after E. coli was perfused.
1DAPEG hour after 48 hours after
1 hour run 3 hours run 1 hour run 3 hours run
# of E. Coli Before After Before After Before After Before After
Trial_1 112.0 2.0 108.0 2.0 147.0 17.0 105.0 12.0
Trial_2 123.0 4.0 103.0 4.0 125.0 12.0 102.0 13.0
Trial_3 126.0 3.0 117.0 3.0 137.0 16.0 100.0 13.0
Trial_4 119.0 2.0 117.0 2.0 132.0 16.0 94.0 11.0
Trial_5 134.0 2.0 106.0 3.0 140.0 19.0 96.0 14.0
Average 122.8 2.6 110.2 2.8 136.2 16.0 99.4 12.6
Deiation 8.2 0.9 6.5 0.8 8.3 2.6 4.5 1.1
Table 4. 4 DAPEG: Number of E. coli inside the channel before and after channels were flushed
with DI water after E. coli was perfused.
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DMAEMA 1 hour after 48 hours after
1 hour run 3 hours run 1 hour run 3 hours run
#of E. Coli Before After Before After Before After Before After
Trial_1 138.0 7.0 84.0 4.0 119.0 23.0 103.0 11.0
Trial_2 147.0 5.0 94.0 4.0 103.0 26.0 108.0 11.0
Trial_3 123.0 6.0 107.0 3.0 127.0 21.0 91.0 12.0
Trial_4 132.0 7.0 110.0 4.0 111.0 31.0 90.0 12.0
Trial_5 124.0 5.0 98.0 4.0 111.0 28.0 100.0 13.0
Average 132.8 6.0 98.6 3.8 114.2 25.8 98.4 11.8
Devatin 10.0 1.0 10.4 0.5 9.1 4.0 7.8 0.8
Table 4. 5 DMAEMA: Number of E. coli inside the channel before and after channels were
flushed with DI water after E. coli was perfused
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Acrylic Acid - 1hour run
Before DI water flush
After DI water flush
No treatment 1 hour after
Surface Modification
4b hours after
Acrylic Acid - 3hours run
Before DI water flush
After DI water flush
No treatment 1 hour after
Surface Modification
48 hour after
Figure 4. 4 Number of E. coli inside the channel treated with Acrylic acid before and after the
channels were flushed with DI water Top: 1 hour flow Bottom: 3 hours flow
140
60
E
10
E
:3
Lf
120 -
100 -
80 -
60 -
40 -
201-
0
140
E
C3
E
:3
E
0
0
ul
0
a)
-0
E
:z
z7
120-
100-
80 -
60-
40 -
201-
0
CHAPTER 4: SURFACE MODIFICATION OF PDMS ELASTOMERS
PIsama - 1 hour run
Before DI water flush
After DI water flush
No treatment 1 hour after
Surface Modification
48 hours after
PIsama - 3hours run
Before DI water flush
After DI water flush
No treatment 1 hour after
Surface Modification
48 hours after
Figure 4. 5 Number of . coli inside the channel treated with Oxygen Plasma before and after
the channels were flushed with DI water Top: 1 hour flow Bottom: 3 hours flow
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Figure 4. 6 Number of E. coli inside the channel treated with DAPEG before and after the
channels were flushed with DI water Top: 1 hour flow Bottom: 3 hours flow
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DMAEMA - 1hour run
Before DI water flush
After DI water flush
No treatment 1 hour after
Surface Modification
48 hours after
DMAEMA - 3hours run
Before DI water flush
After DI water flush
1 hour after
Surface Modification
48 hours after
Figure 4. 7 Number of . coli inside the channel treated with DAMEMA before and after the
channels were flushed with DI water Top: 1 hour flow Bottom: 3 hours flow
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From the data, it can be observed that the anti-biofouling efficacy of each
treatment degrades with time. Furthermore, the run time of E. coli solution had a
minimal affect on the degree of biofouling; the results from 1 hour and 3 hours running
showed not much of a variation from each other. In comparing the efficacy of the four
different surface treatments, it was observed that acrylic acid was the most effective in
improving the non-specific adhesion on PDMS surface followed by plasma, DAPEG, and
DMAEMA..
4.7 Conclusion
Despite the numerous advantages of PDMS for microfluidic devices (such as rapid
prototyping, optical clarity, and gas permeabiity), PDMS elastomers suffer from non-
specific protein adhesion which raises a particular concern for devices to be used in
biological assays due to its hydrophobic surface profile. However, several approaches in
regard to improve the non-specific adhesion have been attempted and some simple yet
effective methods were introduced in this chapter. The efficacy of suggested methods
was investigated by studying the effects of aging of the surface treatment and flow
duration of target solution on the surface-treated microchannels.
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Chapter 5
Development of Artificial Respiration
Device
Most current artificial lung technologies require the delivery of oxygen gas into the blood
via permeable hollow fibers, which depends on membrane diffusivity and differential
pressure to drive gas exchange. In this chapter, we introduce an alternative approach in
which dissolved oxygen (DO) is generated directly from the water content of blood
through the interaction of UV light with a semi-conducting titanium dioxide thin film.
The driving force for this reaction is the displacement of electrons at the photoactive
surface following photon absorption. The resulting generation of electron holes promotes
the oxidation of adjacent water molecules to form active oxygen (AO), which then
decomposes into DO.
5.1 Oxygenation: Theory
The fundamental technology in this so called active oxygenation system lies in the
interaction between the semi-conducting metallic oxide, TiO2 photolytic thin film, and
water contents present in blood via photolytic energy. As one side of the TiO 2 film is
exposed to the light source, the other side of the film (porous film) in contact with blood
generates DO by the following cascade chemical reactions. The following equations
comprise the basis for the photolytic conversion of water into DO and the generation of
carbon dioxide (CO2). 56
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Reaction 1. Photolysis yielding charge separation and active oxygen:
hv + TiO2(anatase) +AO + 2 e-(scb)
where AO designates a solid state active form of oxygen, for example the peroxo
"[TiO 2(0 2 =)2+]", species occurring in the bulk solid phase of the photocatalyst film. The
quotations indicate a surrogate formula for the transient photo-activated catalyst site
within the TiO2 film where the photon was absorbed (i.e. the "hole" or h*) or any
locations within the solid to where the "hole" has migrated via electron exchange other
than the surface. "scb" indicates that the electron produced upon photon absorption is
energetically transferred into the semiconductor band of the titania crystal. As shown
below, AO has a very short life once it migrates to the surface of the photocatalyst that is
in contact with the water supplied from the blood plasma. This migration step reforms
the photon absorption bulk titania film site as follows.
Reaction 2. AO migration to the thin film surface and hydration to adsorbed
peroxy species:
[TiO 2(0 2 7)2+](bulk) + 2[TiO2-OH2](surf) 4 2[TiO2-OOH](surf) + 2Hi(aq) + [TiO2](bulk)
The H20 present on the DO generating surface is supplied from the bulk aqueous phase
(nominally 55.5 molar) and thus does not represent a significant diffusion boundary layer.
Theoretically, water diffusion rate constraints would be expected only at very high lamp
intensities and the highest DO flux values, a limitation not expected for the proposed
technology based on current work. Once at the surface, DO is generated by spontaneous
disproportionation in the following manner.
Reaction 3. Disproportionation
2[TiO 2--OOH](sur) 4 2[TiO2--OH](su> + DO
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The hydrated surface titania species is regenerated at the same time where it is ready to
undergo the next DO generation cycle. The DO diffuses out of the nanoporous surface at
a flux proportional to the lamp intensity, the quantum yield, and the overall rate of
reactions 1, 2 and 3. The DO migrates through the blood plasma where it is taken up
rapidly by red blood cells (RBC) and hemoglobin.
Reaction 4. Oxygenation of hemoglobin
DO + HbRc- O2HbRBc
The hydrogen ions from Reaction 2 transfer through the aqueous phase by the well
known "hopping" mechanism and react with the bicarbonate ion in the blood to enable
the release of carbon dioxide (C0 2) in the manner already involved in the natural lung.
Reaction 5. CO 2 removal using physiological chemistry, involving protonation:
H + HC0 3~ = H2 C0 3
This reaction is followed rapidly by:
Reaction 6. Spontaneous catalyzed dehydration:
H 2CO3  CarbonicAnhydrase > H20 + Co 2t
The chemical substrate for DO formation is a small amount of water derived from the
blood. The formation of DO within the TiO2 ceramic nanoporosity prevents direct
contact of blood cells to the DO formation region. The illumination region is only solid
state and does not contact the aqueous or blood phases.
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5.2 Concept validation
A macroscale test cell has already been constructed by Dasse et al. 13 to determine the
extent to which the indicated chemical conversions occurred during UV illumination of
active surface material. Figure 5.1 is a diagram of the flow cell constructed with the
essential elements of design, a conductive coating of vacuum deposited titanium metal, a
coating of adherent TiO 2 (anatase), and a MnO 2 particulate layer. Ultraviolet (UV) laser
light was introduced to irradiate transparent quartz substrates. This cell was used to
collect pH, electrical current, DO, and gas phase CO2 data as a function of UV irradiation
time with the intensity of 88.1 mW/cm2 filtered at 365 nm wavelength.
Amolyte
IN/OUT
Catholyte
IN/OUT
Acrylic
Silicone gasket
Pt foil (cathode)
Silicone gasket
Acrylic
Silicone S
Nationcm 417
cation
exchange membrane
MnO2
TiO 2(anatase)
Ti metal film
ii III I El tIL~.~
UV Laser light
Figure 5. 1 Flow-through cellfor DO generation and measurement. Schematic illustrating the
individual elements of test cell construction. For purposes of clarity, film thicknesses are not
drawn to scale. Shown are the configuration of the cell components, including photoactive films,
light source, and inlet/outlet for both anolyte and catholyte.
5.2.1 Measurement of dissolved oxygen generation
Glass slide
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A liquid phase reaction chamber was used to monitor DO production. This device uses a
Clark Electrode to measure DO. A two-point calibration procedure was used to the DO
sensor; 2.35 ml of air saturated water at 36C (217.2 nmol/ml) was added to the cell, and
measurements were taken. Then the cell was emptied and flushed with nitrogen to obtain
a zero oxygen measurement. A blood substitute was then added to the batch cell at a
volume of 2.35 ml and a temperature of 36*C. This blood substitute, commonly referred
to as Lockes-Ringer Solution, contains 0.15 M NaCl, 5.6 mM KCl, 4.2 mM CaCl 2*2H 20,
and 7.1 mM NaHCO3. Shortly after this addition, deoxygenation of the solution was
performed by bubbling with nitrogen gas. Once the oxygen content dropped to minimal
levels, the nitrogen bubbling was halted, the photoactive construct and Pt wire counter-
electrode are added, and the reaction chamber is sealed. The process of removing the
sparge tube and sealing the chamber allows some oxygen from the atmosphere to reenter
the system. It takes some time for the oxygen concentration to equilibrate. Once this
occurs, a bias voltage is applied to the cell to produce an electric field to promote
immediate removal of photo-generated electrons but insufficient to produce
electrochemical reactions. A DC power source is used to supply this constant potential to
the system; a Pt wire is connected as the cathode, and the Cu wire extending from the
photoactive construct, and not exposed to the test solution, is connected as the anode.
Electrical current is measured with a high-impedance VOM multimeter. The UV source
is directed to the reaction chamber and the light emitted from the pipe is filtered to
produce light of only 365 nm; the intensity at this wavelength is 88.1 mW/cm 2. Heating
of the solution during illumination was prevented by use of the water jacket surrounding
the reaction chamber; water from a constant temperature circulating bath flowing through
this jacket kept the system at a constant 36*C throughout the experiment. Furthermore,
the light energy associated with activation by a 365 nm UV laser light selectively excites
the TiO2 semiconductor electronic transition (350 - 389 nm band, or about 3.2 eV) with
minimal wasted radiation or transmission. Special dopants may adjust this wavelength to
reduce the energy requirement and even to allow activation within the range of visible
light.
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5.2.2 Observations
The test cell described previously was able to verify that the chemical conversions
occurred only during illumination and in association with the active surface material.
The ability of the thin films of TiO2 to impart energy into the anatase matrix and thereby
to activate the sequence of chemical reactions described earlier was shown by several
criteria.
The generation of active oxygen (AO) at the anatase surface using the energy
from the UV light was evidenced by the disappearance of MB (methyl viologen) dye at
the surface of the anatase film opposite the side irradiated by the UV laser. In turn, the
generation of freed electrons at the anatase surface was evidenced by the appearance of
MB blue color at the surface of the anatase, opposite the site of irradiation. Transport of
the electrons to a conductive surface, where they are then removed so that they do not
recombine with the active oxygen being produced, was evidenced by electrical current in
the anatase semiconductor film to a metallic collector, wire, and amp meter. Electrical
current was found to flow only when the laser was on and never when it was off. The
effect was observed through many on/off cycles. By cycling the UV light, it was shown
that the generation of oxygen only occurred when the cell was illuminated and not
otherwise (Figure 5.2).
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Figure 5. 2 Photolytic induction of dissolved oxygen (DO). Real time demonstration of DO
production in a glass substrate (9 mm x 25 mm) containing 1230A Ti and TiO 2 in 2.35ml of
Locke's Solution (7.2 pH) at 36*C. Bias voltage of +1V was applied using photoactive construct
as the anode and a Pt wire as the cathode, and UV light supplied.
As shown by the comparison of Figure 5.3, the presence of electrical potential
between the conducting layer of the construct and a Pt. counter electrode during
illumination produces an electric field across the photolytic layer, which forces electron
flow away from the TiO2 layer and results in enhanced DO production. When the bias
voltage is removed, and the illumination with UV light ceases, the oxygen concentration
decreases, and the current flow is observed to reverse for a short time. This reversal of
current indicates that during illumination a charge accumulation occurs within the
photolytic construct. Once the light source and bias voltage are turned off, electrons flow
back into the semiconductor layer and oxygen is adsorbed.
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Figure 5. 3 Dependence of DO generation on the application of a bias voltage. Real time
demonstration of DO production under the same conditions described in Figure 5.2, with the
exception that bias voltage in the range of+1 to +2 V was applied.
5.3 Basic Design Elements for a microfluidic capillary
network
Microfluidic blood flow devices with complex channel geometries employing high flow
conditions may be associated with impaired hemocompatibility. Therefore, scaling up of
these networks to accommodate physiologically relevant blood flow rates (L min-l) is
likely to be associated with increased diffusion length and requires through assessment of
the channel geometry, flow rate, and their effects on hemocompatibility. We have
previously examined in detail the relationships between microchannel geometry and
configuration, flow and oxygen diffusion in a microcapillary device. 8 Acknowledging
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the presence of relatively large viscous forces in most microfluidic devices, and the
resulting effect on shear stress,59~60 it has been previously suggested that blood flow
microchannels embodying a branching network require a minimum diameter of 100
gm.61 Although this channel diameter is considerably larger than native pulmonary
capillaries (approximately 5 pm) this diameter is analogous to that of the branching
pulmonary arterial system.62 -5 and thus may constitute a reasonable design template.
Such a design represents a pragmatic compromise since it may itself introduce diffusive
boundary layers not present in native pulmonary capillaries. The mass transfer properties
of microcapillaries with similar diameter was previously characterized analytically
through a simple convective mass transfer model.67 accounting for the diffusivity of
oxygen in blood and the channel diameter (in this case the channel height), and deriving
the Peclet number as a measure of the ratio of the convective to diffusive mass transport
both analytically and experimentally. These results confirmed that hemoglobin saturation
is feasible assuming the above channel configurations and physiological flow lengths.
However, preliminary hemocompatibility experiments to assay thrombogenesis by
microscopic visualization for devices possessing a 100 Rm X 100 pm channel diameter
and a 900 branching configuration during flow (0.1 - 0.64 mL/min) of anticoagulated
blood (ACT > 300 seconds) revealed thrombus at 25% of channel inlets/outlets and
bifurcations as early as 20 minutes.6 (Figure 5.4) As a result, we considered a series of
channel configurations employing y-shaped bifurcations with the goal of minimizing
reduced flow regions and thus reducing the rate of thrombus. The current design also
employed the concept of y-shaped bifurcations, but specifically embodied several novel
design elements described below.
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Figure 5. 4 Image of microchannel bifurcation before and after exposure to flowing blood. The
image on the left shows a channel bifurcation prior to blood contact. The image on the right
shows the same channel bifurcation after 20 minutes of blood flow (the flow rate was 20 ,uL/min
in the inlet channel). The dark areas in the channel are thrombi and areas ofreducedflow. The
arrows indicate the direction offlow. The pattern of thrombus occurred in areas offlow
separation and recirculation.'
Figure 5. 5 Microchannel image following 45 min. of blood perfusion. Occlusion of the majority
of the channel lumen generated prohibitively high back pressure, forcing termination of the test.48
As a basic, scalable building block to minimize damaging tangential shear forces,
we adopted an asymmetrically configured microchannel network design (Figure 5.6).
Our design was similar to the computational model of the human pulmonary capillary
system described by Huang et al. 67 and the network model of endothelialized
microcapillaries proposed by Shin et al.68 The latter device embodied a microcapillary
system with variable channel widths (ranging from 35 pm to 5 mm) and uniform channel
depth (35 pm), and was designed to specifically emulate microvascular physiology and
promote the viability of attached cells. Similarly, Kaazempur-Mofrad et al. 69 proposed a
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variation on this design for the purpose of renal filtration, based on prior fractal-based
design concepts.70 Our microfluidic chip design incorporated the following specific
physical properties: 1) The individual channels possess a high aspect ratio, exhibiting a
width of 1.197 mm and a channel height of 0.1 mm. The width of the inlet and outlet
channels is 3.38 mm, while the overall footprint of the microfluidic array is 2 x 2 cm.
The channel height was derived directly from prior computational and experimental
results. 57 The channel width was chosen empirically on the basis of practical limitations
of current microfabrication capabilities, and was not systematically varied in the current
study. 2) The set of microchannels comprising the 2D aligned chip are each
interconnected with four other channels in a network configuration, thus allowing
alternative flow pathways in the event of single channel occlusion while minimizing the
establishment of detrimental pressure gradients that would be observed using a right
angled hierarchically branching channel architecture.
A
<-1.197mm .1197mm 
1,1 97mm
B
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Figure 5. 6 Microfluidic device employing a network construct. A novel construct was employed
which combined low channel height for efficient diffusion with relatively broad channel width to
minimize shear stress. Shown here are diagrammatic representations of the microchannel
network from the perspective of A) An individual microchannel illustrating the asymmetric
geometry, height of channel is relatively small compared with channel width. B) Top down view
of the overall microchannel network depicting the set of orthogonal interconnections
characteristic of the chip configuration.
5.4 Particle tracking
Particle Image Velocimetry (PIV) is an optical method used to measure velocities and
related properties in fluids. The velocity information is calculated by the motion of the
seeded particles in the fluid. PIV is a non-intrusive technique: The added tracers
generally cause negligible distortion to the fluid flow. 71 In order to analyze velocity
fields in microfluidic devices with high spatial resolution, Micro-Particle Image
Velocimetry (gPIV), which combines fluorescent microscopy and specialized image
interrogation algorithm, has been implemented.72 Micro-PIV works by making
measurements of the displacement of fluorescent particles seeded in the fluid. By
tracking the displacement of these particles during a short time interval fluid velocities in
the microfluidic device can be determined. In our experiment, particle flow was recorded
to the high speed camera (AVI format) and exported as digital image files (TIFF format),
which were analyzed with a gPIV software.73
5.4.1 Flow visualization and particle image velocimetry (PIV)
To display flow in the proposed microchannel device, we prepared a fluid sample
emulating blood consisting of RBC-like particles, 10 pm diameter polystyrene green
fluorescent microspheres (488 nm/ 508 nm ex/em) (Duke Scientific), and determined
local velocity profile with particle tracking.74 75 The fluorescent microspheres were
mixed with deionized water (1:15 v/v) to emulate the intravascular flow patterns of RBCs.
Based on the results of the initial flow simulations, a constant flow of 250 pL min-' was
selected (Harvard syringe pump) for the experiments. Since the individual microspheres
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could not be resolved at this high flow rate, a high speed (1000 frames/sec) camera
(Phantom HD, Vision Research, Inc) was used to capture fluid flow inside the
microfluidic device channels. The captured movies were analyzed using micro-particle
image velocimetry (gPIV), a software method which produces a velocity vector profile of
the non-deforming microspheres present inside the individual channels. By tracking local
displacement of these particles during a short time interval, fluid velocity in the
microfluidic device can be analyzed and represented as local streamlines.
F.5.7.1
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F.5.7.3
Figure 5. 7 Assessment of the attributes of local bloodflow by particle tracking To assess the
local flow patterns of red blood cells within the chip microchannels, 1:15 mixtures (v/v) of 10 pm
size microsphere particles suspended in deionized water were passed through the device at 250
pL min'. F.5.7.1: The device was marked at key junctions by numbers (1-24), and the interfaces
between these junctions labelled by letters (A-J). The flow patterns corresponding to these
locations were identified by streamline construction (F. 5.7.2) and particles tracking (F. 5.7.3)
linking the principal directions of the velocity vectors. The upper set of data (A, D, E, F, G, J)
depicts velocity profiles around post structures, whereas the lower set of data (B, C, H, I) depicts
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velocity profiles around the convergence offlow. These data demonstrate that flow follows well
developed and symmetrical streamlines at all points ofthe microfludic chip.
To assess local flow patterns at key junctions in the chip network, we generated local
velocity vector profiles then represented the aligned velocity vectors as streamlines.
Each region was identified by a number for tracking purposes. In general, the flow
pattern exhibited by the fluorescent microspheres displayed symmetric streamlines
(Figure F-2), i.e. absence of local turbulence. The velocity of the fluid flow was highest
at the inlet and gradually decreased at each junction of mesh bifurcation until it reached
its minimum value at half the distance from the inlet and outlet. After this turning point,
the velocity started to increase again until it reached it maximum value at the outlet.
Particle speed along the same horizontal distance from either the inlet or the outlet was
similarly identical, indicating structural symmetry.
5.5 Blood
Human blood is a suspension of cells in an aqueous solution, i.e. cells in plasma. The
plasma is approximately 90% water by weight, 7% plasma protein, 1% inorganic
substances, and 1% other organic substances. Most of the cellular constituents are
composed of red blood cells (RBCs or erythrocytes) with white blood cells (WBCs or
leukocytes) of various categories making up less than 1/60 0th of the total cellular volume,
and platelets (thrombocytes) less than 1/800 of the cellular volume. There are
approximately 5 million RBCs per mm 3, 5000 to 8000 WBCs per mm3 , and 250,000 to
300,000 platelets per mm in human blood.76
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Figure 5. 8 Blood contents (1) Red Blood Cells, (2) Platelets (stained purple), (3) T-Lymphocyte
white cell (stained green) (4) Monocyte white cell (stained gold) as seen through a scanning
electron microscope."
RBCs form a disk shape, or more specifically thinner in the center and thicker
around the edges, with a diameter of 7.6gm and thickness of 2.8gm roughly and take up
about 50% of the blood volume. They are extremely flexible and can deform through the
blood vessels by aligning the largest dimension paralleled with the direction of the flow.
The main function of RBC is to transport oxygen from the lung to the tissues and return
carbon dioxide back to the lung. The majority of the red blood cell consists of
hemoglobin (approximately 33 % hemoglobin w/w) and its role is to bind molecular
oxygen to its heme irons at the lungs and to deliver it to the tissues. It carries the carbon
dioxide by-product of oxidation back to the lungs, releasing it to the atmosphere. In
contrast, myoglobin stores oxygen in muscle tissue until it is required for metabolic
oxidation rather than transporting oxygen.78
WBCs are spherical and larger than RBCs. There are several types of white blood
cells (leukocytes) and depending on the presence of granules they are categorized into
granulocytes (presence of granules) and agranulocytes (absence of granules).
Granulocytes come in three different types - neutrophils, basophils, and eosinophils.
Neutrophils deal with defense against bacterial infection and inflammatory processes.
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Basophils are responsible for allergic and antigen response. Eosinophils deal with
parastic infection. Agranulocytes include lymphocytes, monocytes, and macrophages.
There are two major types of lymphocytes - B cells and T cells. B cells make antibodies
which bind to pathogens to enable their destruction. T cells coordinate the immune
response and are able to kill virus-infected cells. They also defend against intracellular
bacteria. Monocytes present pieces of pathogens to T cells so that the pathogens may be
recognized again and killed. Monocytes are then able to develop into the phagocytosing
macrophage cell after they migrate from the bloodstream into the tissue and undergo
differentiation.79
Platelets are cell fragments that are involved in the cellular mechanisms of
primary hemostasis. They measure 1.5 - 3.0 gm in diameter. Platelets are activated
when brought into contact with collagen (which is exposed when the endothelial blood
vessel lining is damaged), thrombin, receptors expressed on white blood cells or the
endothelial cells of the blood vessels, a negatively charged surface (e.g., glass), or several
other activating factors. Once activated, they release a number of different coagulation
factors and platelet activating factors. Platelet activation further results in the
scramblase-mediated transport of negatively charged phospholipids to the platelet
surface. These phospholipids provide a catalytic surface for the tenase and
prothrombinase complexes. The platelets adhere to each other via adhesion receptors or
integrins, and to the endothelial cells in the wall of the blood vessel forming a
haemostatic plug in conjunction with fibrin. The high concentration of myosin and actin
filaments in platelets are stimulated to contract during aggregation, further reinforcing the
plug. Besides being the chief cellular effector of hemostasis, platelets are rapidly
deployed to sites of injury or infection and potentially modulate inflammatory processes
by interacting with leukocytes and by secreting cytokines, chemokines and other
inflammatory mediators.80-83 (The term whole blood that will appear in the context
indicates blood that has not been modified in any physical sense.)
A region with a small amount of suspended material exists close to the wall of a
blood vessel, i.e. plasma rich zone next to the wall. Although this layer is very thin, it
has a significant effect on blood rheology. This phenomenon is referred to as the wall-
effect. Table 5-1 summarizes the aforementioned blood contents.
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Composition Concentration
Water 90% (w/w)
Albumins 4.5 - 5.7 x 10-5 g/pL
Proteins 7% (w/w) Globulins 1.3 -2.5 x 10- g/pL
Fibrinogen 1.3 -2.5 x 10- g/&L
Plasma Salts
Dissolved gases
Hormones
Glucose
Metabolites
Nutrients
Red Blood Cells 7 pm 3.6 - 5.4 x 106 &L
Cellular
White Blood Cells 8-20 pm 5.0 - 10.0 x 10 3 g/L
Platelets 1.5-3.0 gm 1.5 - 4.0 x 10 5 g/pL
Table 5. 1 Constituents of human whole blood.6 84 -86
5.5.1 Thrombosis and Hemolysis
A blood clot that is coagulated inside the living organism is called thrombus and the
process is called thrombosis. A coagulation process is a favorable phenomenon which
seals the wounds and stop blood leakage; however it can be extremely dangerous to life
once it occurs inside the blood vessels or in the heart. The process basically involves
polymerization of fibrinogen into fibrin and the principle mechanism is the conversion of
prothrombin into an active enzyme, thrombin. The process is initiated when platelets
adhere to the subendothelial collagen at the point of damage to the endothelium. The
proteins of the coagulation system, through a series of cascading reactions, eventually
form fibrin, the insoluble protein that forms the scaffolding of the thrombus. As blood
flows by the thrombus, more platelets and fibrin are deposited. Then, red blood cells and
white blood cells become entrapped in the thrombus and are integrated into its structure.
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Hemolysis, on the other hand, is the breakage of the red blood cell's membrane,
causing the release of the hemoglobin and other internal components into the surrounding
fluid. Hemolysis in serum or plasma can be visually observed as pink or red. Hemolysis
can occur both in vivo and in vitro. In vivo hemolysis can lead to an anemia and in vivo
hemolysis can lead to an undesirable effect in medical test; test results from all laboratory
disciplines can be affected by hemolysis, especially in chemistry. Hemolysis may cause
certain analytes to be increased due to leakage of red cell constituents (e.g., lactate
dehydrogenase and potassium), or may cause interference in the test method (e.g.,
spectrophotometric methods). The amount of interference will depend on the degree of
hemolysis and on the specific test method being used.
It is essential to determine biocompatibility of all elements of the microfluidic
system during each stage of the design process. The broad question of biocompatibility
will require in depth study before the proposed microfluidic artificial respiration device
can be considered for the marketplace. Our approach for this challenge is to test
biocompatibility of the metal oxide thin film from a materials perspective, effects of
plasma and blood constituents on thin film and DO generation, and the effect of construct
geometry on blood.
Our work on the biocompatibility testing completed thus far includes hemolysis
and preliminary microscopic thrombosis analysis, i.e. the effect of microchannel
geometry on blood flow, rate of hemolysis, and thrombus formation with the goal of
developing microfluidic structures capable of long-term use while minimizing bio-
fouling of the channel. Although more in depth analysis needs to be followed up, our
preliminary study on biocompatibility provides a fine path to accomplish this process
successfully.
5.6 Experimental and Results (Hemocompatibility)
5.6.1 Experimental set up
The mesh network model was composed of a single flow layer of PDMS attached
to blank PDMS substrate. Using PDMS rather than glass as a substrate helped preventing
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thrombus formation on the substrate. Glass substrate generated immediate thrombus
when exposed to the blood. Any sharp edges were avoided in order to minimize possible
thrombosis effect, if any, due to the sharp corners or edges.
3.386mm
Blood In
II
-. Blood Out
1.197mm
Figure 5. 9 Network model design of microfluidic device with channel width of1. 197mm, and
entrance/exit width of 3.386mm.
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Blood goes into
the flow chan-
nel approxi-
mately at 45
degrees
slanted inlet
Cross seci
Blood goes out
of the flow
channel
approximately
at 45 degrees
slanted outlet
Flow Layer
PDMS substrate
ion of the channel
One Cell
PDMS A
F1.1 97mm
Multiple Cells PDWVm
k - 197 " -IITW....
Figure 5. 10 Schematic of the microfluidic device. Single flow layer of PDMS was bonded to the
PDMS substrate. Blood was flown in and out of the channel at a slanted angle in order to
minimize any possible hemolysis and thrombosis effect.
1.197mm 1197mm
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In order to perform the blood flow test through the chips, lOmL of blood was first
directly extracted from a reservoir to a test tube via a 10cc syringe. This was named as a
control unit. Then, another IOmL of blood was transported from a reservoir via a 10cc
syringe to the test tube through the PDMS structure at the flow rate of 0.250mL/min via
syringe pump (Harvard Apparatus). We refer to this as a sample unit. After each cycle
was completed, the above procedure was performed repetitively for 6 to 12 hours. After
both control and sample were collected in the test tube, they were centrifuged for 10
minutes to obtain blood plasma. 2mL of the plasma mixed with lmL of
cyanmethemoglobin were prepared and the absorption rate was measured under
spectrophotometer to calculate the Total Plasma Hemoglobin. After the test was finished,
the device was flushed with saline, ethanol, and saline to get rid of any residual blood
inside the channel in order to confirm that there was indeed no thrombi formation during
the blood perfusion.
5.6.2 Results
Five sets of blood tests were performed to assay the rate of hemolysis and
thrombosis generation in the microfluidic device. Bovine blood obtained from a
slaughterhouse (Lemay, Goftstown, NH) with a normalized hematocrit (Hct) of 29-30
was used (Autocrit Ultra 3) for each experiment. The blood used was 24 to 120 hours old.
No difference was observed in regard to results as a function of blood age. Blood
acquired from the slaughterhouse was treated as follows: A solution of 50,000 units
Heparin in 1000 ml sterile Dextrose (5%) was combined with approximately 4 gallons of
blood obtained from an individual animal. The blood was then gently stirred to distribute
the heparin into the fresh blood. The activated clotting time (ACT) was determined by
conventional clinical methods and was found to be approximately 400 seconds at room
temperature, an accepted value for during clinical cardiopulmonary bypass.87 For assay
of hemolysis, 10 mL samples of blood were collected from the device outlets at each time
point (every 40 minutes for a total duration of 6 or 12 hours) and compared to a control
blood sample that was flowed at the same rate but not through the microfludic device.
Both control and sample were collected and were centrifuged for 10 minutes at 3400 rpm
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to isolate the plasma. After centrifugation, 2 mL of the plasma was mixed with ImL of
cyanmethemoglobin and the absorption rate was measured by a spectrophotometer
(Thermo Spectronic) to calculate the total plasma hemoglobin (TPH) (mg/dl) in terms of
absorption x 242.65 + 3.07.91 Hemolysis was represented as the TPH (sample - control) /
TPH (control) during 6 and 12 hour infusions performed at room temperature, at a flow
rate of 250 pL min-' as predicted by prior simulation. Since the flow rate and sampling
interval did not vary, further normalization procedures 92 were judged to be unwarranted.
Thrombus formation was assessed by microscopic visualization of the channels with an
upright microscope (Industrial Products Group, Inc) at 5 and lOX magnification during
and following flow through the microfluidic chip for 6 and 12 hours at 0.25 mL min~1 .
Since early platelet activation events associated with activation 93-94 are likely to be
undetected by this method, this assay should properly be regarded as a preliminary
assessment of in vivo thrombogenesis.
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Figure 5. 11 Photos of microfluidic device taken after 7 hours of blood perfusion. The possibility
of thrombus formation was studied by microscopy at following a 6 hour perfusion at a constant
flow rate of 0.250 ml min~'. Images are displayed at various locations in the microchip at
approximate magnifications ranging from 5-1OX Images are displayed immediately following
the perfusion period No thrombus was observed at any point of the device. The width of single
channels is 1.197 mm.
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Figure 5. 12 Photos of microfluidic device taken after 12 hours of blood perfusion.
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Figure 5. 13 Photos of micro fluidic device taken after 12 hours of blood perfusion followed by a 
flush with saline. They show no residual thrombus formation inside the channels. 
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Figure 5. 14 Photos of microfluidic device taken after 12 hours of blood perfusion followed by a
flush with saline and additionalflush by ethyl alcohol/saline. Ethyl alcohol treatment removed
all the air bubbles inside the channel.
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Hemolysis Analysis
Flow irregularities related to the geometry of the proposed microfluidic device may result
in enhanced shear stress conditions leading to increased hemolysis or significant
variations of flow rate resulting in enhanced thrombogenesis. To address the former, the
rate of hemolysis was obtained, and represented as the total plasma hemoglobin (TPH)
(sample - control) / TPH (control) obtained over a 7 hour perfusion at a flow rate of
0.250 ml mmin- (Figure 5.18), a flow condition predicted by previoius simulation to entail
minimum hemolysis. Hemolysis rate assayed in this manner was < 5.0% throughout the
entire period of device perfusion. The microfluidic chips were further observed for
possible thrombus formation following these 6 hour perfusion experiments followed by a
washout period. Figure 5.14-15 represents a set of representative microfludic device
images. There was no evidence of thrombus formation at any location in the chip.
Additionally, in a single long-term (12 hours) experiment, we demonstrated that the total
plasma hemoglobin remained stable and not significantly different from control for the
entire infusion period and that there was no visible thrombus formation (Figure 5.19).
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7 hour device run time (continous verfusion with whole blood)
Absorption (A) Total Plasma Hb Hemolysis (%)(mg/dl)
Control 1 0.228 58.3942
3.22
Sample 1 0.236 60.3354
Control 2 0.221 56.6957
-0.86
Sample 2 0.219 56.2104
Control 3 0.223 57.1810
1.26
Sample 3 0.226 57.9089
Control 4 0.221 56.6957
2.10
Sample 4 0.226 57.9089
Control 5 0.221 56.6957
2.10
Sample 5 0.226 57.9089
Control 6 0.222 56.9383
4.09
Sample 6 0.232 59.3648
Control 7 0.228 58.3942
0.82
Sample 7 0.230 58.8795
Control 8 0.229 58.6369
-0.83
Sample 8 0.227 58.1516
Table 5. 2 Hemolysis Analysis. 7 hours of blood perfusion at aflow rate of 0.250mL/min
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Total Plasma Hb of Control and Sample
Flow rate: 0.250mL/min
5 Days Old Bovine Hood
Initial HCT 32 % Tested HCT 29%
Running Time: 7hours
100
90 -
80 -
70 -
60 -
50 -
40 10 0 0 
0 0
0
Time (min)
Figure 5. 15 Assessment of hemolysis following 7 hour blood perfusion. Hemolysis was
determined as afunction offlow through the microfluidic construct (sample) compared withflow
outside of the microfluidic construct (control) in 4 separate experiments. Samples were obtained
every 40 minutes over the course of a 6 hour perfusion at a constant flow rate of 250 uL min'
and total plasma hemoglobin derived by spectrophotometry. The hemolysis percentage was
consistently < 5.0 % and did not increase significantly with the time ofperfusion.
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12 hours running device run time (continous perfusion with whole blood)
Absorption (A) Total Plasma Hb Hemolysis (%)(mg/dl)
Control 1 0.074 21.0261
7.47
Sample 1 0.081 22.7247
Control 2 0.123 32.916
Sample 2 0.083 23.21
Control 3 0.084 23.4526
Sample 3 0.093 25.6365
Control 4 0.086 23.9379
Sample 4 0.081 22.7247
Control 5 0.095 26.1218
Sample 5 0.080 22.482
Control 6 0.157 42.1661
Sample 6 0.165 43.1073 4.5
Control 7 0.181 46.9897
-3.2
Sample 7 0.175 45.5338
Control 8 0.118 37.7027
Sample 8 0.129 34.3719
Control 9 0.124 33.1586
Sample 9 0.125 33.4013
Control 10 0.131 34.8572
Sample 10 0.128 34.1292
Control 11 0.168 43.8352
Sample 11 0.109 29.5189
Control 12 0.099 27.0924 6.69
Sample 12 0.107 29.0336
Control 13 0.116 31.2174
Sample 13 0.106 28.7909
Control 14 0.109 29.5189
Sample 14 0.103 28.063
Control 15 0.104 28.3056
Sample 15 0.106 28.7909
Control 16 0.106 28.7909 0.84
Sample 16 0.107 29.0336 .
Table 5. 3 Hemolysis Analysis. 12 hours of blood perfusion at aflow rate of 0.250mL/min
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Total Plasma Hb of Control and Sample
Flow rate: 0.250mUmin
1 Day Old Bovine Blood
Initial HCT 42 %Tested HCT 30%
Running Time: 12hours
200 -
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140 -
120 -
100 -
80 -
... 60 -
60
0
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Time (min)
Hemolysis Analysis
Flow rate: 0.25OmUmin
1 Day Old Bovine Blood
Initial HCT 42 %Tested HCT 30%
Running Time: 12hours
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0
0E 40-
-10 -
-60
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Figure 5. 16 Assessment of hemolysis following 12 hour blood perfusion. Hemolysis displayed
as afunction oftime through the microfluidic construct (sample) compared withflow outside of
the microfluidic construct (control). Samples were obtained every 40 minutes over course of a 12
hour blood perfusion at a constant flow rate of 250 pL min'
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Chapter 6
Summary and Conclusions
The ultimate goal of our project is to develop a novel microfluidic device incorporating a
photoactive metallic thin film with the capacity to replicate pulmonary capillary
respiration in flowing blood. In order to achieve this task, we investigated manufacturing
parameters for developing microfluidic devices fabricated from the elastomeric polymer,
polydimethylsiloxane (PDMS). In the course of platform development, we have
characterized the curing schedules for the heat-cure double layer PDMS ealstomers and
investigated interlayer bonding mechanics by analyzing the shear and normal forces
required to break the adhesion between the multi-layer PDMS structure. In addition, the
pressure required to cause a burst around the microchannels was investigated as well by
flowing nitrogen gas directly into the channels.
Fabrication parameters that have been considered in manufacturing multi-layer
PDMS devices were catalyst/monomer ratio, primary and secondary bake time, cure
temperature, etc. Considering the fact that ideal mixing ratio of PDMS is 10:1 parts A:B
(both parts contain different intrinsic ratios of catalyst and monomer), we varied the
catalyst/monomer mixing ratio from this reference value to facilitate interlayer bonding.
In the fabrication of two layer devices, the feature size (i.e. aspect ratio) played an
important role in the success of device manufacture. Microchannels with aspect ratio
greater than 10:1 resulted in the frequent failure of multi-layer device fabrication. The
primary curing time was critical to the fabrication of multi-layer structure as well. Too
little primary cure time in individual layers rendered the PDMS layers be too sticky to be
further processed and too much cure time resulted in very poor layer-layer adhesion.
Interlayer bonding analyses (shear, normal, and pressure analysis) revealed the
existence of better mixing ratio of certain monomer/catalyst over another in the strength
of layer-layer adhesion. For instance, bond strength of a 1:3/1:30 device was much
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higher than that of a 1:6/1:15 device. Also, longer secondary baking time produced more
robust interlayer bonding. For our device design, the channels could withstand pressures
from 23 to 50 psi depending on the monomer/catalyst ratio before the burst between the
top and bottom layer occurred.
Based on the manufacture protocols developed, surface modification protocols for
polymers were investigated. While silicone rubber (PDMS) is easy to mold and has
superior optical clarity, its hydrophobic surface makes it susceptible to non-specific
protein adhesion, a particular concern for microfluidic devices to be used in biological
assays. Both chemical and physical modifications of the PDMS surface can increase its
biocompatibility, rendering the surface hydrophilic or entropically unfavorable for
protein adhesion. Most common methods are oxygen plasma treatment, polymer coating
or grafting, and chemical treatment with strong acids. We compared the efficacy of these
techniques, using fluorescently tagged bacteria flowed through microchannels as reporter
particles to measure non-specific adhesion.
Ultimately, utilizing these preliminary data, microscale photocatalytic devices
will be designed in such a way that it can be small enough yet to be practical and have
high quantum yields of oxygen, i.e. to be able to imitate or even exceed the natural
capacity of the alveolar-capillary interface. They will also be designed to overcome a
challenging subject of biocompatibility of microfluidic devices such as hemolysis and
thrombosis, and the final channel network will be constructed to maximize the amount of
blood flow and oxygenation while minimizing the damage to circulating red blood cells.
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